ArticleJournal of clinical laboratory analysis2020
Insulin-like growth factor 1 promotes proliferation and invasion of papillary thyroid cancer through the STAT3 pathway.
Article in Journal of clinical laboratory analysis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 18 citations in OpenAlex.
- Perithyroidal Adipose Tissue Drives Thyroid Tumorigenesis through Adipokine Signaling and Immune Suppression.Research (Washington, D.C.) · 2026Article
- Thyroid cancer: From molecular insights to therapy (Review).Oncology letters · 2025Review
- Shared molecular mechanisms between type 2 diabetes and thyroid cancer: integrated bioinformatics insights for prognostic biomarker discovery.Endocrine connections · 2025Article
- The metabaging cycle promotes non-metabolic chronic diseases of ageing.Cell proliferation · 2024Article
- High aggressiveness of papillary thyroid cancer: from clinical evidence to regulatory cellular networks.Cell death discovery · 2024Review
- Recombinant Human TSH Fails to Induce the Proliferation and Migration of Papillary Thyroid Carcinoma Cell Lines.Cancers · 2024Article
- A review of complex hormone regulation in thyroid cancer: novel insights beyond the hypothalamus-pituitary-thyroid axis.Frontiers in endocrinology · 2024Review
- Monocarboxylate transporter 4 promotes the migration of non‑cancerous L929 fibroblast cells by activating the IGF1/IGF1R/PIK3R3/SGK1 axis.Oncology letters · 2023Article
- E2F3 accelerates the stemness of colon cancer cells by activating the STAT3 pathway.Frontiers in oncology · 2023Article
- Obesity and endocrine-related cancer: The important role of IGF-1.Frontiers in endocrinology · 2023Review
- Analysis of anti-apoptotic PVT1 oncogene and apoptosis-related proteins (p53, Bcl2, PD-1, and PD-L1) expression in thyroid carcinoma.Journal of clinical laboratory analysis · 2022Article
- Mitigation of Ionizing Radiation-Induced Gastrointestinal Damage by Insulin-Like Growth Factor-1 in Mice.Frontiers in pharmacology · 2022Article
- Curcumin inhibits the viability, migration and invasion of papillary thyroid cancer cells by regulating the miR-301a-3p/STAT3 axis.Experimental and therapeutic medicine · 2021Article
- Insulin-like growth factor-1 positively associated with bone formation markers and creatine kinase in adults with general physical activity.Journal of clinical laboratory analysis · 2021Article
- Insulin-like growth factor 1 promotes proliferation and invasion of papillary thyroid cancer through the STAT3 pathway.Journal of clinical laboratory analysis · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPapillary thyroid cancer (PTC) is a kind of thyroid cancer. Previous studies showed that insulin-like growth factor-1 (IGF1) plays an important role in tumorigenesis, development, invasion, and metastasis. However, the function of IGF1 in PTC progression remains unclear.
methodsSeventy-three pairs of PTC tissue specimens and adjacent normal specimens form and normal cell line and PTC cell lines were collected in this study. The immunohistochemistry (IHC) assay was performed to test the expression of IGF1. The RNA isolation and quantitative real-time PCR assays (qRT-PCR assays) and Western blot analysis were used to test mRNA and protein expression. Cell proliferation assay, EdU assay, flow cytometry assay, wound healing assay, and Transwell invasion assay were performed to test cell proliferation, invasion, and apoptosis.
resultsWe found that the expression of IGF1 in PTC tissue samples was higher than that in adjacent normal specimens and was significantly associated with tumor size, TNM staging, and lymph node metastasis. Furthermore, IGF1 treatment significantly increased cell viability in a dose-dependent manner. EdU assay also demonstrated the effect of IGF1 on the proliferation of BCPAP and TPC1 cells. Moreover, IGF1 treatment effectively increased the invasive capacity of BCPAP and TPC1 cells. More importantly, IGF1 treatment could significantly enhance the phosphorylation of STAT3 in BCPAP and TPC1 cells. Moreover, cryptotanshinone (Cryp) treatment reversed the effect of IGF1 treatment on cell viability and invasion of BCPAP and TPC1 cells.
conclusionCollectively, IGF1 promotes proliferation and invasion of PTC progression through the STAT3 signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.